California Public Employees Retirement System Acquires 4,382 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

California Public Employees Retirement System increased its holdings in shares of QuidelOrtho Co. (NASDAQ:QDELGet Rating) by 5.9% in the second quarter, Holdings Channel.com reports. The fund owned 78,302 shares of the company’s stock after buying an additional 4,382 shares during the quarter. California Public Employees Retirement System’s holdings in QuidelOrtho were worth $7,609,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp raised its position in QuidelOrtho by 7.0% during the 1st quarter. State Street Corp now owns 1,106,702 shares of the company’s stock valued at $124,460,000 after purchasing an additional 72,308 shares in the last quarter. Dimensional Fund Advisors LP raised its position in QuidelOrtho by 19.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 610,752 shares of the company’s stock valued at $68,686,000 after purchasing an additional 100,810 shares in the last quarter. Lazard Asset Management LLC raised its position in QuidelOrtho by 934.5% during the 2nd quarter. Lazard Asset Management LLC now owns 514,322 shares of the company’s stock valued at $49,981,000 after purchasing an additional 464,604 shares in the last quarter. TD Asset Management Inc. raised its position in shares of QuidelOrtho by 31.2% in the 2nd quarter. TD Asset Management Inc. now owns 458,302 shares of the company’s stock worth $44,538,000 after acquiring an additional 108,901 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of QuidelOrtho by 6.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 317,543 shares of the company’s stock worth $35,711,000 after acquiring an additional 20,034 shares in the last quarter. 87.20% of the stock is owned by institutional investors.

QuidelOrtho Stock Down 0.5 %

Shares of QDEL stock opened at $88.15 on Thursday. QuidelOrtho Co. has a 1-year low of $66.88 and a 1-year high of $180.06. The stock’s fifty day moving average price is $81.03 and its 200 day moving average price is $89.95. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.66 and a quick ratio of 1.04. The company has a market cap of $5.82 billion, a price-to-earnings ratio of 4.69 and a beta of 0.28.

Wall Street Analysts Forecast Growth

QDEL has been the subject of several recent research reports. StockNews.com initiated coverage on QuidelOrtho in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Citigroup initiated coverage on QuidelOrtho in a research report on Monday, September 19th. They issued a “neutral” rating and a $90.00 price target for the company. JPMorgan Chase & Co. reduced their price target on QuidelOrtho from $100.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, November 3rd. Finally, UBS Group raised QuidelOrtho from a “sell” rating to a “neutral” rating and set a $86.00 price target for the company in a research report on Friday, October 14th. Four analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $99.75.

QuidelOrtho Profile

(Get Rating)

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

Featured Stories

Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Co. (NASDAQ:QDELGet Rating).

Institutional Ownership by Quarter for QuidelOrtho (NASDAQ:QDEL)

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.